ETNB Phase 2b Data Reported!!
Summary: Phase 2b ETNB ENLIVEN data was reported today (3/22/23) & trial met primary endpoints How does this data compare to previous...
top of page
BPIQ Blog
Mar 21, 20232 min read
3 Mental Health Readouts Left as March Movers!
Summary: ITCI, NRXP & VTGN are left in our March Movers list, all are in the mental health category NRXP & VTGN are March Big Movers and...
Mar 20, 20232 min read
IONS & BIIB Tofersen AdComm on Wednesday!
Summary: The IONS and BIIB AdComm meeting for Tofersen is scheduled for this Wednesday, March 22! Briefing docs were released today...
Mar 17, 20231 min read
Biopharma Pulse - 3/13 - 3/17 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Mar 17, 20231 min read
Biotech Q1 '23 Catalyst Countdown
We're coming down to the final weeks of Q1 2023. This past week XBI finished green up ~1%, although it still sits in the mid $70's. See...
Mar 16, 20233 min read
CDTX's Rezafungin PDUFA Coming Soon!
Summary: The CDTX PDUFA for Rezafungin to treat candidemia and invasive candidiasis is scheduled for March 22 Positive Phase 3 data from...
Mar 15, 20232 min read
Over 20 Smid-Cap Biopharmas Presenting at AACR 2023!
Summary: The American Association for Cancer Research (AACR) 2023 Annual Meeting will take place from April 14-19, 2023, abstracts...
Mar 12, 20231 min read
Biotech Catalyst Watchlist Q1 2023 Part 2
Each week we're posting a countdown of the remaining catalysts left in Q1! Last week was a rough week for biotech's with XBI finishing...
Mar 10, 20231 min read
Biopharma Pulse - 3/6 - 3/10 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Mar 7, 20232 min read
ACAD's Trofinetide PDUFA Coming Sunday
Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full...
Mar 6, 20233 min read
ESPR CLEAR Outcomes Data Finally Here!
First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...
Mar 5, 20231 min read
Weekly Biotech Catalyst Watchlist Q1 2023
Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...
Mar 3, 20231 min read
Biopharma Pulse - 2/27-3/3 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Mar 2, 20232 min read
Available Oncology Investor Conference Webcasts
Summary: Several recent oncology investor conferences are still available to the public, including all company webcasts These conferences...
Mar 1, 20231 min read
10 Rare Disease Catalysts to Watch
First posted 3/10/2023; last updated 5/1/2023 Summary: Many exciting rare diseases catalysts are coming throughout the year See the table...
Feb 25, 20231 min read
Weekly Biotech Catalyst Watchlist Feb/March
Last week was a tough week for biotech, XBI (biotech ETF) saw a 6% pullback, see the biggest news from last week, including a full table...
Feb 24, 20231 min read
Biopharma Pulse - 2/20-2/24 Weekly Review
Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...
Feb 22, 20234 min read
Reata Pharmaceuticals (RETA) Concerns For Upcoming PDUFA Decision
Summary: Reata Pharmaceuticals has a PDUFA data for Omaveloxolone for FA 2/28/23. The previous PDUFA date was extended 3 months after...
Feb 22, 20233 min read
Upcoming Pegozafermin NASH Readout!
Summary: The upcoming readout from ETNB includes Phase 2b data from the pegozafermin trial in NASH. This is a Suspected Mover for Q1...
Feb 21, 20231 min read
Blood Cancer & Disease Biotech Stock Catalyst Watchlist
Last updated 4/11/23 Summary: Many exciting blood cancer & disease catalysts are coming throughout the year See the table below for some...
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page